Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Subtyping and MRD-driven Induction in Pediatric AML (GMCAII)
NCT06221683Phase 2Recruiting
- Sponsor
- Children's Hospital of Soochow University
- Start
- Jan 2024
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax, sorafenib, gilteritinib and avapritinib in acute myeloid leukemia (AML) (2 arms), sponsored by Children's Hospital of Soochow University. Primary endpoints: Rate of Complete Remission or Complete Remission with Incomplete Count Recovery with Negative MRD at Day 32, Event-Free Survival at 72 months and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
venetoclaxsorafenibgilteritinibavapritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06221683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221683.